Aberrant MYB gene expression is seen in approximately 60% of all ACC patients, compared to MYBL1, which is reported in approximately 35% of patients who are negative for the MYB–NFIB fusion [46]. The gene discussed is MYBL1; the disease is adrenal cortex carcinoma.